AUTHORS
Kamal Kumar, PhD, Shancy Jacob, PhD2, Diana Gabriela Calvopina Chavez, PhD3, Yasuhiro Kosaka, PhD4, Rodrigo Huallanca De La Cruz5, Jesse Rowley, PhD6
AFFILIATIONS
1 Molecular Medicine Program, Salt Lake City, Utah, United States
2 Molecular Medicine Program, Salt Lake City, Utah, United States
3 Molecular Medicine Program, Salt Lake City, Utah, United States
4 Molecular Medicine Program, Salt Lake City, Utah, United States
5 Molecular Medicine Program, Salt Lake City, Utah, United States
6 Division of Hematology & Hematologic Malignancies, Department of Internal Medicine, Salt Lake City, Utah, United States, Molecular Medicine Program, Salt Lake City, Utah, United States
ABSTRACT
Background: Mitochondria regulate platelet functional responses that contribute to hemostasis and thrombosis (Wang et al., Redox Biology 87, 2025). Coordinated mitochondrial fusion and fission maintain mitochondrial homeostasis, and our previous studies demonstrated that disruption of either the fusion protein MFN2 or the fission GTPase DRP1 alters platelet number and function (Jacob et al., Circulation Research 134, 2024; Jacob et al., Blood 142, 2023). Because Fis1 is a receptor for DRP1 involved in mitochondrial fission, we investigated whether Fis1 regulates platelet mitochondrial morphology and function.
Methods: Megakaryocyte/platelet-lineage Fis1-deficient mice were generated using Platelet Factor 4 (Pf4)-Cre × Fis1 fl/fl mice and compared with Pf4-Cre-negative littermate controls. Complete blood counts were measured by Hemavet. Mitochondrial morphology and number were assessed by confocal microscopy, and mitochondrial content by TOM20 immunoblotting. Agonist-induced αIIbβ3 activation and α-granule secretion were quantified by flow cytometry. PF4 release was assessed by confocal microscopy, and platelet aggregation and ATP release by lumi-aggregometry. Procoagulant platelet formation was quantified by annexin V binding to phosphatidylserine.
Results: Fis1-deficient platelets exhibited normal mitochondrial morphology, distribution, and number by confocal microscopy, with approximately 3–4 distinct mitochondria per platelet, comparable to littermate controls. However, TOM20 abundance was modestly increased by immunoblotting, suggesting increased mitochondrial content. Loss of Fis1 resulted in significantly reduced platelet counts with increased mean platelet volume (P<0.001). In response to multiple agonists, Fis1-deficient platelets showed reduced αIIbβ3 activation and P-selectin exposure (P<0.001). Consistent with impaired granule secretion, thrombin-induced PF4 release was reduced, as was ATP release following collagen (P<0.01) or PAR4 peptide stimulation (P<0.05). These defects were accompanied by reduced maximal platelet aggregation (P<0.05). Procoagulant platelet formation following thrombin plus convulxin stimulation was also reduced (P<0.01).
Conclusions: Fis1 deficiency causes thrombocytopenia and broadly impairs platelet activation, granule secretion, aggregation, and procoagulant activity despite preserved mitochondrial morphology. These findings demonstrate that Fis1 is required for normal platelet function and support a role for Fis1 beyond canonical mitochondrial fission.
DISCLOSURES
Kamal Kumar, PhD: No relevant conflicts of interest to declare.